SecBot SecBot
8-K ·Filed Feb 26, 2026

DCTH

DELCATH SYSTEMS, INC.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001628280-26-012004
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of accelerating revenue growth, improved profitability, strong clinical data supporting HEPZATO, and an optimistic 2026 outlook suggests continued momentum. Traders should monitor procedure volume trends and the pace of new center activations as leading indicators of future revenue.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.00
T+0 close · Feb 26, 2026 · via day close
Latest settled
+27.22%
T+60 · $11.45
Vs SPY
+19.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $9.00entry
  2. T+1 · 9mo ago −1.11%α −0.66% · $8.90
  3. T+5 · 9mo ago +0.89%α +2.02% · $9.08
  4. T+20 · 8mo ago +1.44%α +7.85% · $9.13
  5. T+60 · 6mo ago +27.22%α +19.47% · $11.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Delcath Systems reported strong financial results for Q4 and full year 2025, with full-year revenue up 129% year-over-year to $85.2 million and full-year net income of $2.7 million. The company also issued 2026 guidance calling for at least $100 million in revenue, representing over 17% growth, driven by continued HEPZATO adoption and clinical momentum from positive trial data.

Key Financial Metrics

Revenue
$85.2M
+129.0% YoY
Adj. EPS
$0.07
GAAP: $0.08
Guidance
$100 million
raised
Gross Margin
86%

Key Facts

  • Full year 2025 revenue was $85.2 million, up 129% from $37.2 million in 2024
  • HEPZATO KIT revenue grew to $78.8 million in 2025 from $15.1 million in 2024
  • Full year 2025 net income was $2.7 million vs. a net loss of $26.4 million in 2024
  • Non-GAAP adjusted EBITDA was $25.1 million in 2025 vs. a loss of $2.5 million in 2024
  • Company guided to at least $100 million in total revenue for 2026, implying >17% growth

Financial Impact

Revenue grew 129% YoY to $85.2M in 2025 with a dramatic swing from a $26.4M net loss in 2024 to $2.7M net income in 2025, and guidance points to continued strong growth with >$100M revenue expected in 2026

revenuenet incomeepsebitdaguidance

Segment Breakdown

SegmentRevenue
HEPZATO KIT$78.8M
CHEMOSAT$6.4M

Risk Factors

  • R&D and SG&A expenses increased significantly in 2025, which could pressure margins if revenue growth slows
  • The stock may already reflect positive expectations, making it vulnerable to any miss on the $100M+ 2026 revenue guidance
  • Reliance on continued HEPZATO adoption and reimbursement stability

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-012004
Document: dcth-20260226.htm0001628280-26-012004
Document: 0001628280-26-012004-index-headers.html0001628280-26-012004
Document: 0001628280-26-012004-index.html0001628280-26-012004
Document: 0001628280-26-012004.txt0001628280-26-012004

Track record

12 reports on DCTH

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $21.38 Now $19.87 −7.06% settles Feb 10
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $20.27 Now $19.87 −1.97% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $14.82 Now $19.87 +34.08% settles Feb 2
  4. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $14.86 Now $19.87 +33.71% settles Jan 26
  5. Oct 19, 202628d ago SC 13D/A Neutral 4/10 Entry $14.37 Now $19.87 +38.27% settles Jan 14
  6. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $11.77 to $16.48 Now $19.87 +68.89% ▲ +40.08% +35.68% vs SPY
  7. May 14, 202626w ago 8-K Neutral 3/10 Entry $11.46 to $16.67 Now $19.87 +73.39% ▲ +45.46% +41.87% vs SPY
  8. May 7, 202627w ago 8-K Neutral 5/10 Entry $11.24 to $13.04 Now $19.87 +76.78% ▲ +16.01% +12.18% vs SPY
  9. Apr 2, 202632w ago DEFA14A Neutral 3/10 Entry $9.63 to $12.59 Now $19.87 +106.33% ▲ +30.74% +16.58% vs SPY
  10. Mar 2, 202637w ago Insider Cluster Bullish 6/10 Entry $8.93 to $10.83 Now $19.87 +122.51% ▲ +21.28% +11.95% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026